Kornimate/medical-research-clean huggingface dataset:
non-surgical treatment of peri-implantitis with ultrasonic carbon tip

Conditions: Peri-Implantitis; Alveolar Bone Loss

Summary: as the frequency of dental implants increases, the incidence of complications and peri-implant diseases also increases. early diagnosis and treatment of the disease is important to prevent consequences up to implant loss. non-surgical treatment is the recommended treatment in the first stage due to its shorter duration and low morbidity rate. non-surgical treatment of peri-implantitis provides clinical improvements such as reduced bleeding on probing (20-50%) and, in some cases, reduced pocket depth (≤ 1 mm). this study aims to clinically and radiographically compare two different mechanical treatments in patients with mild and moderate peri-implantitis.

60 patients with at least one implant with mild to moderate peri-implantitis, defined as 2-4 mm radiographic reduced bone level, bleeding index (bi) ≥ 2, and probing pocket depth (ppd) ≥ 4 mm will be randomly allocated to test and control groups, receiving titanium curettes or ultrasonic carbon tips debridement, respectively. treatment was performed at baseline. plaque index (pi), gingival index (gi), periodontal pocket depth (pd), bleeding on probing (bop) gingival recession (gr) and clinical attachment level (cal) will be measured at four sites per implant and recorded by examiner at baseline, one, three, six and twelve months. pus will be recorded as present/not present. the radiographic marginal bone level changes will be calculated at baseline, third months, sixth months and 12 months.

Eligibility criteria:
inclusion criteria: 1. adult patients (≥18 years old) 2. systemically healthy (asa class 1 and asa class 2) 3. full-mouth plaque scores ≤20% 4. implant had been in function for more than 6 months 5. absence of plaque around the implant 6. consent to complete all follow-up visits exclusion criteria: 1. mobile implant 2. overhanging restorations that prevent access to the implant for clinical measurements 3. unresolvable technical complications that can cause peri-implantitis 4. presence of active periodontal disease 5. implants with a history of peri-implantitis treated using graft materials 6. use of drugs that cause gingival hyperplasia 7. systemic antibiotic use in the last 3 months 8. acute and chronic medical conditions that prevent the patient from participating in the study 9. presence of uncontrolled severe peri-implantitis from neighbouring implants 10. history of radiotherapy in the head and neck region 11. receiving acute chemotherapy 12. current corticosteroid therapy
amh and functional hypothalamic amenorrhea

Conditions: Amenorrhea Secondary

Summary: the purpose of this study is to analyze amh levels in patients with prolonged fha (more than 2 years). based on previous studies, we can assume that prolonged fha may mimic a condition of primary hypogonadotropic hypogonadism, due to a lasting interruption of gonadotropin release. furthermore, after the resumption of the spontaneous menstrual cycle, we will reanalyze amh levels, which we hypothesize to find higher. if our hypotheses are confirmed correct, we could support the thesis that amh is not a good index of ovarian reserve in patients with functional hypothalamic amenorrhea.


Eligibility criteria:
inclusion criteria: * women aged 15-34 years. * diagnosis of functional hypothalamic amenorrhea (for at least 2 years). * signature of informed consent. exclusion criteria: * polycystic ovary syndrome * taking oral contraceptives in the previous three months * other clinically relevant endocrinopathies * positive map-test (medroxyprogesterone acetate test) * estroprogestin replacement therapy * autoimmune disorders * failure to sign informed consent
trial of preoperative hepatic and regional arterial chemotherapy (phrac) to prevent postoperative liver metastasis of colorectal cancer

Conditions: Colorectal Neoplasms

Summary: the purpose of this study is to investigate whether preoperative hepatic and regional arterial chemotherapy are able to prevent liver metastasis and improve overall survival in patients receiving curative colorectal cancer resection.

we administered fudr, mmc and oxaliplatin as preoperative hepatic and regional arterial chemotherapy (phrac) to patients with stage ii or stage iii colorectal cancer without apparent liver metastasis based on a thorough preoperative evaluation. the study endpoints were disease-free survival, overall survival, and liver metastasis-free survival as evaluated by intent-to-treat analysis.

Eligibility criteria:
inclusion criteria: * age \< 75 years with histologically proven adenocarcinoma of the colon or rectum * no severe major organ dysfunction * who performance status of 0 or 1 * no prior cancer therapy * stage ii (t3-4, n0, m0) or stage iii (t0-4, n1-2, m0) disease (according to the 1997 revision of the international union against cancer tnm staging system) as determined by a preoperative evaluation that included colonoscopy and an abdominal computed tomography (ct) scan exclusion criteria: * age \>= 75 * severe major organ dysfunction * who performance status of \>1 * prior cancer therapy * stage i or stage iv

Keywords: colorectal neoplasms regional liver neoplasm metastasis
physical exercise versus cognitive-behavioral therapy (cbt) for panic disorders: a randomised controlled trial

Conditions: Panic Disorder

Summary: the purpose of this study is to compare manualised physical exercise conducted in groups to manualised cognitive-behavioral therapy conducted in groups as treatment for panic disorder with or without agoraphobia.


Eligibility criteria:
inclusion criteria: * written informed consent obtained * clinical diagnosis of panic disorder with and without agoraphobia according to the diagnostic and statistical manual of mental disorders (dsm-iv-tr, 4th ed., text revision; american psychiatric association, 2000), established through administration of structural clinical interview for dsm-iv axis i disorders (scid i; first, spitzer, gibbon, \& williams, 1995). exclusion criteria: * brain-organic disorders according to dsm-iv-tr * the presence of psychotic disorders according to dsm-iv-tr, established through administration of scid i * present substance-abuse * medical condition that excludes participation in physical activity * major depressive disorder according to dsm-iv-tr established through administration of scid i.

Keywords: panic disorder physical exercise cognitive-behavioral therapy manualized
online intervention to modify interpretation biases in depression

Conditions: Depression; Cognitive Change

Summary: cognitive biases have been found to be possible causal and vulnerability factors for depression. there is empirical evidence on the presence of negative emotional biases in interpretation in people with depressive symptoms. a whole new area of research, called cognitive bias modification (cbm), is focused on targeting negative cognitive emotional biases to investigate its impact on clinical symptoms. a recent meta-analysis has shown that this type of programs are effective in reducing cognitive biases but there is still controversy on their clinical value to reduce symptoms. the purpose of the study is to create a brief online intervention aimed to reduce negative emotional cognitive biases present in depression and to analyze its impact on clinical symptoms and well-being.

more specifically, the intervention is framed within the area of cbm but it is rooted on techniques and change procedures used in cognitive-behavioral therapies. while original cbm studies train participants to change cognitive biases in an automatic manner, by forcing individuals to find positive outcomes to ambiguous scenarios, this new intervention focuses on teaching participants the meaning of emotional cognitive biases and how to modify them by using an effortful type of processing (i.e., looking for adaptive alternative interpretations to ambiguous stories). the study has been design to overcome some of the limitations that have been pointed out in this emerging research area. firstly, although there are recent efforts to understand how interpretation, attention and memory cognitive biases may be related, it is still not clear how they interact with each other. for this purpose, some authors have pointed out the need to use longitudinal data to see how one process may affect each other over time. secondly, different systematic reviews and meta-analyses have investigated the moderating role of variables that may be affecting the heterogeneity of results found in cbm interventions. mental imagery has been found to be a useful tool to help participants in their changing process, while there is no preferred number of sessions for these interventions. this study will help shed some light into this factors by using mental imagery during four sessions online.

Eligibility criteria:
inclusion criteria: * present (phq-9) or past (did) episode of depression. * access to internet * fluent in spanish language exclusion criteria: * being under any psychological treatment * having a psychotic condition * having any cognitive impairment or condition that do not allow to follow the program * serious auditory or visual impairments

Keywords: cognitive biases cognitive bias modification depression online intervention cognitive bias interpretation
ph ii of a novel anti-angiogenic agent in combination with chemotherapy for the treatment of non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: the purpose of this study is to determine the efficacy of ct-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous nsclc


Eligibility criteria:
for additional information, please contact the bms oncology clinical trial information service at 855-216-0126 or email mycancerstudyconnect@emergingmed.com. please visit www.bmsstudyconnect.com for more information on clinical trial participation. inclusion criteria: * ecog performance status (ps) \<=1 * histologically or cytologically confirmed, stage iiib (malignant pleural effusion), stage iv or recurrent nsclc * measurable disease by recist guidelines exclusion criteria: * evidence of predominantly squamous-cell histology * known cns metastases * any prior antineoplastic systemic regimens for nsclc * excessive risk of bleeding (including use of therapeutic anticoagulation) and history of thrombotic or embolic cerebrovascular accident * gross hemoptysis (≥1/2 tsp of red blood) * uncontrolled hypertension * clinically significant cardiovascular disease * history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis
project shine (sleep health initiative for equity): culturally informing a sleep extension intervention for african american adults

Conditions: Obesity; Insufficient Sleep

Summary: the proposed research aims to reduce obesity-related health disparities by promoting healthy lifestyle behaviors among african americans (aas), given the high disease burdens associated with low physical activity, insufficient sleep, and obesity. there will be two phases to the proposed research. phase 1 (aim 1) will encompass formative research and community engagement activities, and phase 2 (aim 2a and 2b) will be a randomized clinical trial. the primary goal of aim 1 is to conduct in-depth qualitative interviews in order to: (1) better understand sleep-related social contextual factors, knowledge, behaviors, and beliefs, and (2) discuss and receive feedback on an existing sleep intervention design and materials. the primary goal of aim 2 is to explore the feasibility, satisfaction, and preliminary efficacy of a sleep intervention to increase sleep and physical activity (pa) among sedentary and short sleeping (≤6 hrs/night) african american adults with overweight/obesity, compared to a contact control group. (aim 2a) an additional exploratory (aim 2b) examines changes in cancer-relevant biomarkers between those who received the intervention vs the control condition (n = 20). data will be collected from a sample of 20 participants (10 per condition) who volunteer to have their blood drawn pre- and post-intervention. there are two phases of the study, and information gained during phase 1 (aim 1) will be used to inform phase 2 (aim 2). thus, additional modifications to the protocol will be submitted prior to engagement in phase 2.


Eligibility criteria:
inclusion criteria: phase 1: * not meeting physical activity guidelines * age range: 21 to 75 years * body mass index: ≥25.0 kg/m2 * average self-reported habitual sleep duration of ≤6 hours * self-identify as black or african american phase 2: * not meeting physical activity guidelines * age range: 21 to 75 years * body mass index: ≥25.0 kg/m2 * average self-reported habitual sleep duration of ≤6 hours * self-identify as black or african american exclusion criteria: phase 1: * self-reported organ-related disorder (copd, cardiac arrhythmia, gastro-esophageal disorder) * pregnant or less than 4 months postpartum * infant living in household less than 1 year old phase 2: * self-reported organ-related disorder (copd, cardiac arrhythmia, gastro-esophageal disorder) * pregnant or less than 4 months postpartum * infant living in household less than 1 year old
recombinant human bone morphogenetic protein-2(rhbmp-2) in patients with osteoporosis after lumbar fusion

Conditions: Osteoporosis; Spinal Fusion

Summary: rhbmp-2 has been used to promote spinal fusion. despite potential risk of complications, satisfied results could be obtained with low dose of rhbmp-2. effect of early bone formation has been validated using rat ovariectomy osteoporosis model. however, whether it functioned in patients with osteoporosis remained unknown. in this study, the investigators intend to investigate whether rhbmp-2 promotes early bone formation in patients with osteoporosis after transforaminal lumbar interbody fusion (tlif).

pseudoarthrosis and many complications associated with iliac crest bone graft (icbg) has prompted the spine surgeons to seek alternative methods to promote rate of spinal fusion. the rhbmp-2 received fda approval in 2002 for use as an alternative to autograft for single-level anterior lumbar interbody fusion (alif). many studies reported equivalent or better fusion rates. recent studies, however, identified complications related to rhbmp-2 use such as osteolysis, graft subsidence, and retrograde ejaculation and other urological complications. overdose of rhbmp-2 in patients may lead to complications mentioned above. a recent randomized controlled trial in 2022 confirmed a low dose usage of rhbmp-2 promoted fusion after tlif (21.mg per fusion level) without increase in complications. current fusion methods achieve interbody fusion by filling the cage in the central region of the intervertebral space with bone graft material. however, the early fusion rates (at 3 and 6 months postoperatively) are often unsatisfactory. according to present literatures, the 3-month and 6-month fusion rates have ranged from 2.9% to 43.1% and 30% to 68.8%, respectively. although a lack of fusion may be asymptomatic, it may potentially lead to complications, even a reoperation. in addition, failure to achieve early fusion may result in a delayed return to work, and reduced patient satisfaction, especially in patients with osteoporosis. whether rhbmp-2 may lead to higher and early fusion rate in osteoporosis patient remains unknown. in this study, the investigators intend to compare the time it takes to achieve osseous union/fusion and the clinical efficacy of using rhbmp-2 to control group in tlif. the rhbmp-2 in the study is produced by a domestic enterprise (hangzhou jiuyuan gene engineering co .,ltd., hangzhou, china).

Eligibility criteria:
inclusion criteria: * patients diagnosed with degenerative lumbar diseases. * patients underwent one-level tlif * osteoporosis (dxa t≤-2.5) * complete preoperative and follow-up data (imaging and health-related quality of life) exclusion criteria: * history of previous spinal surgery * inflammatory and neoplastic diseases

Keywords: rhbmp-2, lumbar fusion, fusion rate, osteoporosis
egfr-tki with chemotherapy in nsclc patients with both egfr mutation and bim deletion polymorphism

Conditions: Non-Small-Cell Lung Cancer

Summary: bim deletion polymorphism might be associated with a poor clinical response to egfr-tkis in patients who had nsclc with egfr mutations. in the study, the investigators want to use egfr-tki with chemotherapy as first line treatment in stage iiib/iv nsclc patients with both egfr mutation and bim deletion polymorphism.

bim deletion polymorphism was a poor clinical response marker to egfr-tkis in nsclc patients who had egfr mutations. in the study, the investigators want to use egfr-tki with chemotherapy as 1 st treatment in stage iiib/iv nsclc patients with both egfr mutation and bim deletion polymorphism.

Eligibility criteria:
inclusion criteria: signed informed consent age \>=18 years histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic stage iv non-small cell lung cancer (nsclc) a cytologic diagnosis is acceptable (i.e., fna or pleural fluid cytology) must have measurable or non-measurable disease must be able to comply with study and follow-up procedures exclusion criteria: small cell, carcinoid, or mixed small cell lung cancer malignancies within 3 years except for adequately treated carcinoma in situ of -the cervix or basal or squamous cell skin cancer symptomatic or untreated brain metastases prior systemic chemotherapy for nsclc unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible) history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (iv) alimentation, or prior surgical procedures affecting absorption pregnancy or lactation

Keywords: nsclc bim egfr mutation
long-term impact of maxillomandibular advancement osteotomy on sleep apnea patients

Conditions: Obstructive Sleep Apnea

Summary: background maxillomandibular advancement surgery (mma) has demonstrated high success rates, improving both the apnea-hypopnea index and associated patient' quality of life (qol), in patients diagnosed with obstructive sleep apnea syndrome (osas). however, clinical relapse has been described in the target population, especially when associated with significant weight gain. literature reporting the long-term impact of mma for osas is lacking. the surgeons of the division of maxillofacial surgery already started to perform this type of surgery in 1995. objectives the investigators aim to evaluate the long-term (minimum 15 years post-surgery) biologic and qol impact of mma in patients with osas. the biologic impact refers to the stability of hard and soft tissues and polysomnographic results. study design retrospective study both pre- en postoperative clinical imaging, polysomnography and quality of life questionnaires will be retrieved from all patients that were surgically treated with an mma by one surgeon (cdc) between 01/11/1995 and 01/12/1999. conclusion short-term data have shown high success rates for mma in osas patients. however, long-term data are lacking. this retrospective study might provide us with more information about the incidence of clinical relapse fifteen to twenty years after surgery.


Eligibility criteria:
inclusion criteria: * clinically confirmed diagnosis of osas * treated with an mma between 01/11/1995 and 01/12/1999 by one surgeon (cdc) exclusion criteria: * not following abovementioned criteria

Keywords: maxillomandibular advancement osteotomy long-term results quality of life polysomnographic measurements skeletal stability
effect of obesity on cyclosporine blood trough level in nephrotic syndrome patients

Conditions: Nephrotic Syndrome

Summary: this study aims to assess the effect of obesity on therapeutic response and safety of cyclosporine trough level in nephrotic syndrome patients and calculating a suitable weight-based dose.

1. ethical committee approval has been obtained from ethics committee of faculty of medicine, alexandria university. 2. agreement from all participants should be taken in this clinical study by assigning an informed consent. 3. nephrotic diseased patients,will be recruited from alexandria main university hospital (amuh). 4. the 74 participants will be non-randomly assigned into 2 groups. 5. the control group is non-obese nephrotic patients with bmi \<25 kg/m2 will receive receive cyclosporine capsule with conventional initial dose 3 mg/kg/day using actual weight. 6. the case interventional group is obese nephrotic patients with bmi\> 25kg/m2 will receive cyclosporine capsule with the best weight based dose to achieve the targeted therapeutic trough level and targeted urinary protein/ creatinine ratio. 7. all patients will be subjected to : * first visit: full patient history, anthropometrics (weight, hight, bmi, fat %, water %, muscles% and clinical examination. calculate the initial cyclosporine dose 3mg/kg/day in 2 divided doses based on actual weight. * second visit after one month: blood sample withdrawal for measuring trough level, lipid profile and thyroid profile, urinary sample to measure upcr if patients don't reach to targeted therapeutic trough level and targeted urinary protein/ creatinine ratio,re-modifying the dose and repeat the labs after another one month in third visit. * finally find the best weight can be used to achieve the targeted therapeutic trough level and targeted urinary protein/ creatinine ratio, and its relation with fat content and lipid profile 8. the appropriate statistical tests will be hold according to study design and parameters (parametric and non-parametric) to evaluate the significance of the results. 9. results, conclusion, discussion and recommendations will be given.

Eligibility criteria:
inclusion criteria: * obese and overweight nephrotic syndrome adult patients receiving cyclosporine for more than one month with prednisolone. (bmi\>25 kg/m2) * normal or underweight individuals nephrotic syndrome adult patients receiving cyclosporine for more than one month with prednisolone. (serving as control group) exclusion criteria: * hepatic patients liver cirrhosis (moderate to severe liver impairment) * cancer patients, * pregnant and lactating female patients

Keywords: cyclosporine obese patients lipoproteins